Loading...
•
Jun 30
Atai Q2 2025 Earnings Report
Atai Life Sciences reported a narrower net loss in Q2 2025 compared to the prior year, with slight revenue growth and steady R&D investment amid progress in its psychedelic treatment pipeline.
Key Takeaways
Atai Life Sciences reduced its net loss to $27.7 million in Q2 2025 and posted $719,000 in revenue, while advancing key clinical programs including BPL-003 and VLS-01. The company strengthened its financial position and continued progressing strategic milestones.
Net loss attributable to shareholders narrowed to $27.7 million in Q2 2025 from $57.3 million in Q2 2024.
Q2 2025 revenue was $719,000, up from $273,000 in Q2 2024.
Cash and cash equivalents totaled $61.9 million, with total assets of $189.2 million.
Company expects to fund operations into the second half of 2027 following additional July funding.
Atai
Atai
Atai Revenue by Segment
Revenue by Segment
License Revenue
CapyFin.com Forward Guidance
Atai anticipates topline Phase 2b and 2a data for BPL-003 in Q3 2025 and is planning for a regulatory meeting with the FDA, while its VLS-01 and EMP-01 trials continue enrolling.
Positive Outlook
- BPL-003 met all endpoints in Phase 2b and showed rapid, durable antidepressant effects.
- End-of-Phase 2 FDA meeting for BPL-003 planned for Q3 2025.
- Company expects funding runway into the second half of 2027.
- EMP-01 and VLS-01 clinical trials remain active and progressing.
- Atai plans strategic combination with Beckley Psytech to consolidate leadership in psychedelics.
Challenges Ahead
- Primary endpoint not met in inidascamine Phase 2b trial.
- Delays in site activation and recruitment for VLS-01 Phase 2 trial.
- Higher G&A expenses due to strategic restructuring and redomiciliation efforts.
- Potential risks around pending shareholder approvals for Beckley combination.
- Operating cash use in Q2 totaled $31.9 million, pressuring near-term liquidity.